NEI Research News

On February 14, 2013, the U.S. Food and Drug Administration approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP).

In 2008, a team of scientists funded by the National Eye Institute (NEI), a part of the National Institutes of Health, reported major progress in the treatment of an inherited form of progressive blindness using gene therapy.

Changes in how genes in the immune system function may result in age-related macular degeneration (AMD), the leading cause of visual impairment in older adults, based on preliminary research conducted by National Institutes of Health (NIH) investigators.

Researchers have developed a new prosthetic technique that can restore vision to blind mice. The approach could potentially be further developed to improve sight in blind people.

The NEI, part of the National Institutes of Health (NIH), has become the first U.S. government agency to develop a formal collaborative research and training agreement with the United Kingdom’s National Health Service (NHS).

At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD).

Researchers recently demonstrated that human blood cells can be converted into a variety of eye cells important for vision.

NantWorks LLC has released the new LookTel Recognizer app designed to help people who are blind or visually impaired recognize everyday objects by using their iPhone camera.

Around Halloween time, health experts fear that consumers will harm their eyes with unapproved decorative contact lenses.

The Argus II retinal prosthesis, developed by Second Sight, Inc., with funding from the National Eye Institute (NEI), was recognized September 8, 2011, in honor of being the 8 millionth patent issued by the United States Patent and Trademark Office.